Trial Profile

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Cancer; Malignant melanoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms ITHER

Most Recent Events

30 Jul 2021 Status changed from active, no longer recruiting to recruiting.
30 Jul 2021 Planned End Date changed from 1 Jul 2019 to 1 Dec 2022.
30 Jul 2021 Planned primary completion date changed from 1 Jul 2019 to 1 Mar 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com